|Traded as||BSE: 500087
BSE SENSEX Constituent
CNX Nifty Constituent
|Founder||Dr. K. A. Hamied|
|Headquarters||Mumbai, Maharashtra, India|
|Y. K. Hamied, Chairman
Subhanu Saxena (CEO)
|Products||Pharmaceuticals and diagnostics|
|Revenue||₹104.83 billion (US$1.7 billion) (2013-14)|
|₹18.80 billion (US$300 million) (2012-13)|
|₹13.89 billion (US$220 million) (2013-14)|
|Total assets||₹109.68 billion (US$1.7 billion) (2013-14)|
|Total equity||₹100.91 billion (US$1.6 billion) (2013-14)|
Number of employees
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India; Belgium, & Surrey in the European Union; and Miami, Florida, in the United States; with manufacturing facilities in Goa (eight), Bengaluru (one), Baddi (one), Indore (one), Kurkumbh (one), Patalganga (one), and Sikkim (one), along with field stations in Delhi, Pune, and Hyderabad. Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
It was founded by Dr. Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in 1935 in Mumbai. The name of the Company was changed to 'Cipla Limited' on 20 July 1984. In the year 1985, US FDA approved the company's bulk drug manufacturing facilities.
In 1994, Cipla launched Deferiprone, the world’s first oral iron chelator. In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient).
In 2012, the company slashed prices of three life-saving cancer drugs by 50-64%.
Products and services
Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate. They are the world's largest manufacturer of antiretroviral drugs
Cipla has 34 manufacturing units in 8 locations across India and has presence in 170 countries. Exports accounted for 48% ₹49.48 billion (US$790 million) of its revenue for FY 2013-14. Cipla spent INR 517 cr. (5.4% of revenue) in FY 2013-14 on R&D activities. The primary focus areas for R&D were development of new formulations, drug-delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.
As on 31 March 2013, the company had 22,036 employees (out of which 2,455 were women (7.30%) and 23 were employees with disabilities (0.1%)). During the FY 2013-14, the company incurred ₹12.85 billion (US$200 million) on employee benefit expenses.
The equity shares of Cipla are listed on the Bombay Stock Exchange, where it is a constituent of the BSE SENSEX index, and the National Stock Exchange of India, where it is a constituent of the CNX Nifty. Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.
As on 30 September 2014, the promoter group, Dr. Y. K. Hamied and his family, held around 36.80% equity shares in Cipla. Around 148,000 individual shareholders held approx. 18.67% of its shares. LIC is the largest non-promoter shareholder with approx. 6.45% shareholding in the company by the end of September 2013.
|Shareholders (as on 31-March-2014)||Shareholding|
|Foreign Institutional Investors (FII)||23.32%|
|Private Corporate Bodies||04.68%|
|Mutual Funds and UTI||04.43%|
Awards and recognitions
- In 2012, Cipla received the Thomson Reuters India Innovation Award.
- Cipla won Dun & Bradstreet American Express Corporate Awards for 2006.
- In 2005, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.
- In 1980, Cipla won Chemexcil Award for Excellence for exports.
Sale of emergency pregnancy termination pills over-the-counter
In August 2007, Cipla launched pregnancy termination pill 'i-pill'. The morning-after pill was sold as the easiest way to avoid unwanted pregnancies, but drew criticism as it was sold over-the-counter (hence not requiring a medical prescription) and for the probable side effects. The drug contained twice the amount of main ingredient ‘levonorgestrel’ as compared to similar drugs such as Norlevo (Win Medicare) and Ecee2 from German Remedies. One industry specialist noted that there was no evidence across the world of the drug being safe for females below 16 years of age. An industry insider, who also has products in oral contraception, said the amount of active ingredient in the pill could cause problem in women with high blood pressure, heart disease. The same analyst noted that the drug was not safe for people with problems such as liver disease, diabetes, migraines or asthma. Hence, if the drug was distributed over the counter then there was no practical way to prevent people with aforementioned issues or people below 16 years from buying the tablet.
Sale of generic drugs
In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, and when the drug's patent holder, ICI, protested to the Indian government, the CEO of Cipla successfully lobbied the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs,and instead to allow only patents that covered methods to make drugs. This change made propranolol and other patented drugs, generic and led to criticism of both India's patent laws and Cipla. India reinstated patents on drugs in 2005.
- "Annual Report 2013-14" (PDF). Cipla. 22 August 2014. Retrieved 17 September 2014.
- "Business Responsibility Report 2013-14" (PDF). Cipla. 15 July 2014. Retrieved 17 September 2014.
- Cipla to buy 51% in Yemen distribution company | Business Line
- Cipla invests $1.5 million in Chase Pharma | Business Line
- Cipla gets 345 million rand South African contract | Business Line
- Cambridge varsity honour for Cipla chief | Business Line
- http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?symbol=CIPL.BO BusinessWeek
- How a little blue pill changed Cipla’s fortunes | Business Line
- "Top Companies by Market Capitalisation". Money Control. 17 September 2014. Retrieved 17 September 2014.
- Cipla to sell MSD’s HIV drug in India | Business Line
- Cipla, Hetero to roll out biosimilar drug | Business Line
- "About us - History". Cipla Limited. Retrieved 3 November 2013.
- "Company History - Cipla Ltd.". Economic Times. Retrieved 3 November 2013.
- "Company Profile - Cipla Limited". IndiaInfoline.com. Retrieved 3 November 2013.
- "Indian drug company offers cheap AIDS drugs". USA Today. 19 June 2001. Retrieved 3 November 2013.
- "Cipla again cuts cancer drug prices by up to 64%". Times of India. 9 November 2012. Retrieved 3 November 2013.
- "cipla ltd (CIPLA:Natl India)". Business Week. Retrieved 7 November 2013.
- "AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India". PR Newswire. 8 August 2007. Retrieved 4 November 2013.
- "Cipla Limited: Revenue and Financial Data". Hoovers. Retrieved 2 November 2013.
- "Cipla in the pink of health". Business Standard. 25 September 2013. Retrieved 5 November 2013.
- "Cipla Limited". BSEindia.com. Retrieved 2 November 2013.
- "Scripwise Weightages in S&P BSE SENSEX". BSE India. Retrieved 2 November 2013.
- "NTPC Limited". NSE India. Retrieved 2 November 2013.
- "Download List of CNX Nifty stocks (.csv)". NSE India. Retrieved 2 November 2013.
- "CIPLA - Shareholding belonging to the category : "Public and holding more than 1% of the Total No.of Shares"". MoneyControl.com. 30 September 2013. Retrieved 4 November 2013.
- DBT, Cipla get Thomson Reuters India innovation awards
- "Pharmaceutical sector award". Dun & Bradstreet. 10 September 2006. Retrieved 3 November 2013.
- "Asian Paints, Cipla in Forbes list". Economic Times. 17 November 2005. Retrieved 3 November 2013.
- "Cipla rises on morning-after pill". Hindustan Times. 5 October 2007. Retrieved 3 November 2013.
- "Cipla Launches i-pill". Financial Express. Retrieved 3 November 2013.
- "‘i-pill’ by Cipla draws criticism from experts". Financial Express. 27 October 2007. Retrieved 3 November 2013.
- "The Treasure of Mumbai". Wired Magazine. December 2006. Retrieved 4 November 2013.
- "Indian Generic Drug Maker Targets Sad Americans". biohealthinvestor.com. 3 January 2007. Retrieved 4 November 2013.